FDA Approves RINVOQ Product Under Rare Pediatric Disease Priority Review Voucher

Summary

The FDA has approved a product redeeming a priority review voucher for RINVOQ, a rare pediatric disease treatment, following a review of its supplemental application submitted on March 16, 2022.